<p>A variety of approaches are used to evaluate the immunogenicity of a specific candidate HIV-1 vaccine, X. These approaches may or may not include testing immunogenicity of the HIV-1 vaccine itself in non-primates (e.g., rodents, rabbits, guinea pigs, etc.) or NHPs. In addition, the immunogenicity of an SIV or SHIV analogue of the HIV-1 vaccine may be tested in NHPs; this is done before NHP efficacy trials, which require challenge of NHPs with SIV or SHIV. Currently, neither immunogenicity nor challenge studies in NHPs are required preclinical assessments for candidate HIV-1 vaccines.</p
Study design for testing immunogenicity of αDCIR.HIV5pep and αCD40.HIV5pep vaccines.</p
Recent findings have brought optimism that development of a successful human immunodeficiency virus ...
An efficacious vaccine to HIV-1 is direly needed to stem the global pandemic. Immunogens that elicit...
<div><p>This strategy would be required for advancing an HIV-1 vaccine candidate to human testing.</...
The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain u...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
The immune correlates of risk analysis and recent non-human primate (NHP) challenge studies have gen...
Purpose of reviewThe development of a preventive HIV vaccine remains an unresolved challenge. Animal...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult ov...
Numerous human immunodeficiency virus (HIV)-1 vaccines have been developed over the last three decad...
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major ...
In earlier work, we showed that a single dose of an SIV vaccine based on a serotype 2 recombinant a...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
Study design for testing immunogenicity of αDCIR.HIV5pep and αCD40.HIV5pep vaccines.</p
Recent findings have brought optimism that development of a successful human immunodeficiency virus ...
An efficacious vaccine to HIV-1 is direly needed to stem the global pandemic. Immunogens that elicit...
<div><p>This strategy would be required for advancing an HIV-1 vaccine candidate to human testing.</...
The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain u...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
The immune correlates of risk analysis and recent non-human primate (NHP) challenge studies have gen...
Purpose of reviewThe development of a preventive HIV vaccine remains an unresolved challenge. Animal...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult ov...
Numerous human immunodeficiency virus (HIV)-1 vaccines have been developed over the last three decad...
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major ...
In earlier work, we showed that a single dose of an SIV vaccine based on a serotype 2 recombinant a...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
Study design for testing immunogenicity of αDCIR.HIV5pep and αCD40.HIV5pep vaccines.</p
Recent findings have brought optimism that development of a successful human immunodeficiency virus ...
An efficacious vaccine to HIV-1 is direly needed to stem the global pandemic. Immunogens that elicit...